BIOMAT Database Logo BIOMAT Database Logo

HIV-1 reverse transcriptase inhibitor design using artificial neural networks. 1994

I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
Biomedical Department, Institute of Bioorganic and Petroleum Chemistry, Kiev, Ukraine.

Artificial neural networks were used to analyze and predict the human immunodeficiency virus type 1 reverse transcriptase inhibitors. The training and control sets included 44 molecules (most of them are well-known substances such as AZT, dde, etc.). The activities of the molecules were taken from literature. Topological indices were calculated and used as molecular parameters. The four most informative parameters were chosen and applied to predict activities of both new and control molecules. We used a network pruning algorithm and network ensembles to obtain the final classifier. Increasing of neural network generalization of the new data was observed, when using the aforementioned methods. The prognosis of new molecules revealed one molecule as possibly very active. It was confirmed by further biological tests.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000465 Algorithms A procedure consisting of a sequence of algebraic formulas and/or logical steps to calculate or determine a given task. Algorithm
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
Improving fold resistance prediction of HIV-1 against protease and reverse transcriptase inhibitors using artificial neural networks.
August 2017, BMC bioinformatics,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
Artificial neural networks: non-linear QSAR studies of HEPT derivatives as HIV-1 reverse transcriptase inhibitors.
January 2004, Molecular diversity,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
HIV-1 reverse transcriptase inhibitor from Phyllanthus niruri.
November 1992, AIDS research and human retroviruses,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
Exploring the dNTP -binding site of HIV-1 reverse transcriptase for inhibitor design.
December 2021, European journal of medicinal chemistry,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
RegnANN: Reverse Engineering Gene Networks using Artificial Neural Networks.
January 2011, PloS one,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
October 2004, Current HIV research,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
Dual inhibitor design for HIV-1 reverse transcriptase and integrase enzymes: a molecular docking study.
February 2020, Journal of biomolecular structure & dynamics,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
A novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
January 1992, Advances in experimental medicine and biology,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
[RILPIVIRINE -- a novel HIV-1 non-nucleoside reverse transcriptase inhibitor].
March 2013, Klinicka mikrobiologie a infekcni lekarstvi,
I V Tetko, and Tanchuk VYu, and N P Chentsova, and S V Antonenko, and G I Poda, and V P Kukhar, and A I Luik
HIV-1 reverse transcriptase inhibitors.
June 2007, Applied microbiology and biotechnology,
Copied contents to your clipboard!